2024-08-092025-08-312025-08-31falseSC818971NASSAR HEALTHCARE LTD2026-05-06falseiso4217:GBPxbrli:pureSC8189712024-08-08SC8189712025-08-31SC8189712024-08-092025-08-31SC8189712024-08-07SC8189712024-08-08SC8189712024-08-082024-08-08SC818971bus:SmallEntities2024-08-092025-08-31SC818971bus:AuditExempt-NoAccountantsReport2024-08-092025-08-31SC818971bus:FullAccounts2024-08-092025-08-31SC818971bus:PrivateLimitedCompanyLtd2024-08-092025-08-31SC818971core:WithinOneYear2025-08-31SC818971core:AfterOneYear2025-08-31SC818971core:WithinOneYear2024-08-08SC818971core:AfterOneYear2024-08-08SC818971core:ShareCapital2025-08-31SC818971core:SharePremium2025-08-31SC818971core:RevaluationReserve2025-08-31SC818971core:OtherReservesSubtotal2025-08-31SC818971core:RetainedEarningsAccumulatedLosses2025-08-31SC818971core:ShareCapital2024-08-08SC818971core:SharePremium2024-08-08SC818971core:RevaluationReserve2024-08-08SC818971core:OtherReservesSubtotal2024-08-08SC818971core:RetainedEarningsAccumulatedLosses2024-08-08SC818971core:LandBuildings2025-08-31SC818971core:PlantMachinery2025-08-31SC818971core:Vehicles2025-08-31SC818971core:FurnitureFittings2025-08-31SC818971core:OfficeEquipment2025-08-31SC818971core:NetGoodwill2025-08-31SC818971core:IntangibleAssetsOtherThanGoodwill2025-08-31SC818971core:ListedExchangeTraded2025-08-31SC818971core:UnlistedNon-exchangeTraded2025-08-31SC818971core:LandBuildings2024-08-08SC818971core:PlantMachinery2024-08-08SC818971core:Vehicles2024-08-08SC818971core:FurnitureFittings2024-08-08SC818971core:OfficeEquipment2024-08-08SC818971core:NetGoodwill2024-08-08SC818971core:IntangibleAssetsOtherThanGoodwill2024-08-08SC818971core:ListedExchangeTraded2024-08-08SC818971core:UnlistedNon-exchangeTraded2024-08-08SC818971core:LandBuildings2024-08-092025-08-31SC818971core:PlantMachinery2024-08-092025-08-31SC818971core:Vehicles2024-08-092025-08-31SC818971core:FurnitureFittings2024-08-092025-08-31SC818971core:OfficeEquipment2024-08-092025-08-31SC818971core:NetGoodwill2024-08-092025-08-31SC818971core:IntangibleAssetsOtherThanGoodwill2024-08-092025-08-31SC818971core:ListedExchangeTraded2024-08-092025-08-31SC818971core:UnlistedNon-exchangeTraded2024-08-092025-08-31SC818971core:MoreThanFiveYears2024-08-092025-08-31SC818971core:Non-currentFinancialInstruments2025-08-31SC818971core:Non-currentFinancialInstruments2024-08-08SC818971dpl:CostSales2024-08-092025-08-31SC818971dpl:DistributionCosts2024-08-092025-08-31SC818971core:LandBuildings2024-08-092025-08-31SC818971core:PlantMachinery2024-08-092025-08-31SC818971core:Vehicles2024-08-092025-08-31SC818971core:FurnitureFittings2024-08-092025-08-31SC818971core:OfficeEquipment2024-08-092025-08-31SC818971dpl:AdministrativeExpenses2024-08-092025-08-31SC818971core:NetGoodwill2024-08-092025-08-31SC818971core:IntangibleAssetsOtherThanGoodwill2024-08-092025-08-31SC818971dpl:GroupUndertakings2024-08-092025-08-31SC818971dpl:ParticipatingInterests2024-08-092025-08-31SC818971dpl:GroupUndertakingscore:ListedExchangeTraded2024-08-092025-08-31SC818971core:ListedExchangeTraded2024-08-092025-08-31SC818971dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-08-092025-08-31SC818971core:UnlistedNon-exchangeTraded2024-08-092025-08-31SC818971dpl:CostSales2024-08-082024-08-08SC818971dpl:DistributionCosts2024-08-082024-08-08SC818971core:LandBuildings2024-08-082024-08-08SC818971core:PlantMachinery2024-08-082024-08-08SC818971core:Vehicles2024-08-082024-08-08SC818971core:FurnitureFittings2024-08-082024-08-08SC818971core:OfficeEquipment2024-08-082024-08-08SC818971dpl:AdministrativeExpenses2024-08-082024-08-08SC818971core:NetGoodwill2024-08-082024-08-08SC818971core:IntangibleAssetsOtherThanGoodwill2024-08-082024-08-08SC818971dpl:GroupUndertakings2024-08-082024-08-08SC818971dpl:ParticipatingInterests2024-08-082024-08-08SC818971dpl:GroupUndertakingscore:ListedExchangeTraded2024-08-082024-08-08SC818971core:ListedExchangeTraded2024-08-082024-08-08SC818971dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-08-082024-08-08SC818971core:UnlistedNon-exchangeTraded2024-08-082024-08-08SC818971core:NetGoodwill2025-08-31SC818971core:IntangibleAssetsOtherThanGoodwill2025-08-31SC818971core:LandBuildings2025-08-31SC818971core:PlantMachinery2025-08-31SC818971core:Vehicles2025-08-31SC818971core:FurnitureFittings2025-08-31SC818971core:OfficeEquipment2025-08-31SC818971core:AfterOneYear2025-08-31SC818971core:WithinOneYear2025-08-31SC818971core:ListedExchangeTraded2025-08-31SC818971core:UnlistedNon-exchangeTraded2025-08-31SC818971core:ShareCapital2025-08-31SC818971core:SharePremium2025-08-31SC818971core:RevaluationReserve2025-08-31SC818971core:OtherReservesSubtotal2025-08-31SC818971core:RetainedEarningsAccumulatedLosses2025-08-31SC818971core:NetGoodwill2024-08-08SC818971core:IntangibleAssetsOtherThanGoodwill2024-08-08SC818971core:LandBuildings2024-08-08SC818971core:PlantMachinery2024-08-08SC818971core:Vehicles2024-08-08SC818971core:FurnitureFittings2024-08-08SC818971core:OfficeEquipment2024-08-08SC818971core:AfterOneYear2024-08-08SC818971core:WithinOneYear2024-08-08SC818971core:ListedExchangeTraded2024-08-08SC818971core:UnlistedNon-exchangeTraded2024-08-08SC818971core:ShareCapital2024-08-08SC818971core:SharePremium2024-08-08SC818971core:RevaluationReserve2024-08-08SC818971core:OtherReservesSubtotal2024-08-08SC818971core:RetainedEarningsAccumulatedLosses2024-08-08SC818971core:NetGoodwill2024-08-07SC818971core:IntangibleAssetsOtherThanGoodwill2024-08-07SC818971core:LandBuildings2024-08-07SC818971core:PlantMachinery2024-08-07SC818971core:Vehicles2024-08-07SC818971core:FurnitureFittings2024-08-07SC818971core:OfficeEquipment2024-08-07SC818971core:AfterOneYear2024-08-07SC818971core:WithinOneYear2024-08-07SC818971core:ListedExchangeTraded2024-08-07SC818971core:UnlistedNon-exchangeTraded2024-08-07SC818971core:ShareCapital2024-08-07SC818971core:SharePremium2024-08-07SC818971core:RevaluationReserve2024-08-07SC818971core:OtherReservesSubtotal2024-08-07SC818971core:RetainedEarningsAccumulatedLosses2024-08-07SC818971core:AfterOneYear2024-08-092025-08-31SC818971core:WithinOneYear2024-08-092025-08-31SC818971core:Non-currentFinancialInstrumentscore:CostValuation2024-08-092025-08-31SC818971core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-08-092025-08-31SC818971core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-08-092025-08-31SC818971core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-08-092025-08-31SC818971core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-08-092025-08-31SC818971core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-08-092025-08-31SC818971core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-08-092025-08-31SC818971core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-08-092025-08-31SC818971core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-08-092025-08-31SC818971core:Non-currentFinancialInstrumentscore:CostValuation2025-08-31SC818971core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-08-31SC818971core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-08-31SC818971core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-08-31SC818971core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-08-31SC818971core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-08-31SC818971core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-08-31SC818971core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-08-31SC818971core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-08-31SC818971core:Non-currentFinancialInstrumentscore:CostValuation2024-08-08SC818971core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-08-08SC818971core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-08-08SC818971core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-08-08SC818971core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-08-08SC818971core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-08-08SC818971core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-08-08SC818971core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-08-08SC818971core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-08-08SC818971bus:Director12024-08-092025-08-31SC818971bus:Director22024-08-092025-08-31

NASSAR HEALTHCARE LTD

Registered Number
SC818971
(Scotland)

Unaudited Financial Statements for the Period ended
31 August 2025

NASSAR HEALTHCARE LTD
Company Information
for the period from 9 August 2024 to 31 August 2025

Directors

Emily Alice Nassar
Mahmoud Kazem Nassar

Registered Address

29/10 Brighouse Park Cross
Cramond
Edinburgh
EH4 6GW

Registered Number

SC818971 (Scotland)
NASSAR HEALTHCARE LTD
Balance Sheet as at
31 August 2025

Notes

2025

£

£

Fixed assets
Tangible assets340
40
Current assets
Debtors417,409
Cash at bank and on hand72,228
89,637
Creditors amounts falling due within one year5(22,831)
Net current assets (liabilities)66,806
Total assets less current liabilities66,846
Net assets66,846
Capital and reserves
Called up share capital125
Profit and loss account66,721
Shareholders' funds66,846
The financial statements were approved and authorised for issue by the Board of Directors on 6 May 2026, and are signed on its behalf by:
Mahmoud Kazem Nassar
Director
Registered Company No. SC818971
NASSAR HEALTHCARE LTD
Notes to the Financial Statements
for the period ended 31 August 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in Scotland. The company's registered office is 0/1, 66 Highburgh Road, Glasgow, G12 9EN.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard), and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS102 have been applied other than where additional disclosure is required to show a true and fair view.
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Going concern
At the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operation for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts. Medical fees from services provided are recognised when the service is delivered to the customer.
Current taxation
Current tax is recognised in profit or loss and represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.
Tangible fixed assets and depreciation
Tangible assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and impairment losses. Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases: Computers - 33.33% straight line The gain or loss arising on the disposal of an asset is determined as the difference between the sales proceeds and the carrying value of the asset, and is credited or charged to the profit and loss account.
Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and on hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less. Bank overdrafts are disclosed separately within current liabilities.
Financial instruments
The company only enters into basic financial instruments that result in the recognition of financial assets like trade debtors and creditors. These are measured at amortised cost and are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Statement of comprehensive income.
2.Average number of employees

2025
Average number of employees during the year3
3.Tangible fixed assets

Office Equipment

Total

££
Cost or valuation
Additions6060
At 31 August 256060
Depreciation and impairment
Charge for year2020
At 31 August 252020
Net book value
At 31 August 254040
At 08 August 24--
4.Debtors: amounts due within one year

2025

£
Other debtors3,337
Prepayments and accrued income14,072
Total17,409
5.Creditors: amounts due within one year

2025

£
Taxation and social security19,094
Accrued liabilities and deferred income3,737
Total22,831
6.Directors advances, credits and guarantees
As at 31 August 2025 the company was owed £3,337 from the director M K Nassar. This was repaid in full after the period end.
7.Share capital
On incorporation Ordinary Share Capital of £100 was issued. This was re-organised with an additional 25 shares issued during the period. The share capital at the period end was made up as follows:- 2025 50 Ordinary A shares of £1 each - 50 50 Ordinary B shares of £1 each - 50 25 Ordinary C shares of £1 each - 25 ____ 125 ____